Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Retained Earnings (2016 - 2025)

Lisata Therapeutics' Retained Earnings history spans 13 years, with the latest figure at -$564.7 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 3.03% year-over-year to -$564.7 million; the TTM value through Dec 2025 reached -$564.7 million, down 3.03%, while the annual FY2025 figure was -$564.7 million, 3.03% down from the prior year.
  • Retained Earnings reached -$564.7 million in Q4 2025 per LSTA's latest filing, down from -$42000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$42000.0 in Q4 2023 to a low of -$564.7 million in Q4 2025.
  • Average Retained Earnings over 3 years is -$315.3 million, with a median of -$515.4 million recorded in 2023.
  • Peak YoY movement for Retained Earnings: tumbled 1304819.05% in 2024, then soared 99.99% in 2025.
  • A 3-year view of Retained Earnings shows it stood at -$42000.0 in 2023, then crashed by 1304819.05% to -$548.1 million in 2024, then fell by 3.03% to -$564.7 million in 2025.
  • Per Business Quant, the three most recent readings for LSTA's Retained Earnings are -$564.7 million (Q4 2025), -$42000.0 (Q3 2025), and -$557.4 million (Q2 2025).